Menéndez et al.’s study involving 70 patients with prostate cancer revealed that the inclusion of ozone in treatment may alleviate RT adverse effects and cause a decrease in prostate-specific antigen (PSA) figures [153]. The gene discussed is KLK3; the disease is Familial prostate cancer.